Guggenheim lowers ArriVent BioPharma stock price target to $28

Guggenheim cut its price target on ArriVent BioPharma (AVBP) to $28 from $30, keeping a Buy rating. The stock is down 53% in six months, trading at $13.01. The firm adjusted estimates after Q3 2026 results, including a Phase 3 miss for FURVENT. ArriVent has $393.2M in cash, expected to last until mid-2028. Analysts have mixed views on its prospects.

Original reporting
Published Nov 16, 2026, 12:56 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 1:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$AVBP
Bearish
medium confidence
Mentioned
$AVBP
Relevance
5/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$AVBPBearishLow
01

Why it matters

Analyst target revisions reflect immediate market sentiment but do not change the underlying cash position or pipeline timeline.

02

Market read

The price‑target cuts may trigger short‑term volatility in AVBP, while the broader biotech sector remains sensitive to trial outcomes.

03

What to watch

Upcoming data from the firm’s firmonertinib trial in 2027 could offset short‑term pressure.

Relevance 5/10Novelty 3/10Timing: post‑earnings reaction

Background

ArriVent BioPharma reported Q3 2026 results, including a Phase 3 trial miss and early data from other candidates.

Company-level read

Ticker impact

$AVBPBearishMedium confidence
Context

Guggenheim lowered its price target on ArriVent BioPharma (AVBP) to $28 from $30 after the company's Q3 2026 results and a Phase 3 miss.

Expected impact

downward pressure as investors price in the lower target

Evidence & confidence

Analyst target reductions typically lead to short-term price declines, especially after a miss in a pivotal trial.

Market effects

Biotech sector may see broader caution on trial‑risk stocks.

US biotech investors may adjust exposure to early‑stage oncology assets.

Limited to investors tracking US‑listed biotech companies.

Counterpoint

Some investors may view the target cut as an overreaction given long‑term pipeline potential.

Key entities

  • Guggenheim

    Lowered price target to $28.

  • ArriVent BioPharma

    Biotech firm with multiple trial updates.

Related articles

$AVBPHighAI 8/10

ArriVent Reports Q3 2026 Results; FURVENT Misses Primary Endpoint, ALPACCA Enrollment Continues

ArriVent BioPharma (AVBP) reported Q3 2026 results, with R&D expenses at $38.9M and net loss widening to $40.3M. The FURVENT trial missed its primary endpoint, but ALPACCA enrollment continues. ARR-217 showed promising preliminary data, and ARR-002's first-in-human study began. Cash reserves are $393.2M, expected to last until mid-2028. AVBP stock closed at $14.16, up 3.81%.

$AVBPMed

ArriVent BioPharma Reports Third Quarter 2026 Financial Results

ArriVent BioPharma, Inc. (AVBP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ArriVent BioPharma Reports Third Quarter 2026 Financial Results · Continued enrollment in pivotal Phase 3 ALPACCA study in EGFR PACC-mutant NSCLC · Presented encouraging Phase 1 data for ARR-217, a CDH17-targeted ADC for gastrointestinal malignancies at ESMO · Dosed

$AVBPMedAI 8/10

Truist raises ArriVent BioPharma stock price target on drug data

Truist raised its price target for ArriVent BioPharma (AVBP) to $21, citing positive early data for ARR-217 in treating metastatic colorectal cancer. The drug showed a 44.8% preliminary response rate and favorable tolerability. Truist expects Phase 1b data in early 2027. AVBP's stock is down 27% from last week, trading at $15.26. Other analysts have mixed views following a Phase 3 trial failure for firmonertinib.

$AVBPMedAI 9/10

ArriVent BioPharma’s ARR-217 Shows 44.8% Response Rate in Colorectal Cancer Study

ArriVent BioPharma (NASDAQ:AVBP) reported ARR-217 showed a 44.8% response rate in colorectal cancer study. Key data: 50% in RAS-mutant, 42% in RAS wild-type, 43.5% in irinotecan-treated patients. Phase Ib study ongoing; Phase III trial planned by 2027 end. Common adverse events included anemia, neutropenia, and diarrhea. Company also advancing ARR-002 and firmonertinib in NSCLC.